Study of rBet v1 Tablets

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

483 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-10-31

Study Completion Date

2009-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Tolerability Study of rBet v1 SLIT Tablets

NCT00889460

COMPLETED PHASE1

Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1

NCT00396149

COMPLETED PHASE1

Dose Range Finding Study With rBet v1-FV - in Adult Patients With Birch Pollen-Allergic Seasonal Rhinoconjunctivitis

NCT01490411

Allergic Rhinoconjunctivitis

COMPLETED PHASE2

Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

NCT00309062

Birch Pollen Allergy

COMPLETED PHASE3

Immunological and Histological Evaluation of Specific Immunotherapy With Recombinant Hypoallergenic Derivative

NCT00841516

Allergic Rhinoconjunctivitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Birch Pollen-related Rhinoconjunctivitis Rhinitis, Allergic, Seasonal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

One sublingual tablet of matching placebo daily during approximately 5.5 months

2

12.5 µg rBet v 1

Group Type EXPERIMENTAL

rBet v 1

Intervention Type BIOLOGICAL

One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months

3

25 µg rBet v 1

Group Type EXPERIMENTAL

rBet v 1

Intervention Type BIOLOGICAL

One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months

4

50 µg rBet v 1

Group Type EXPERIMENTAL

rBet v 1

Intervention Type BIOLOGICAL

One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

One sublingual tablet of matching placebo daily during approximately 5.5 months

Intervention Type BIOLOGICAL

rBet v 1

One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months

Intervention Type BIOLOGICAL

rBet v 1

One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months

Intervention Type BIOLOGICAL

rBet v 1

One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo control rBet v 1.0101 rBet v 1.0101 rBet v 1.0101

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptomatic birch pollen-related allergic rhinoconjunctivitis for at least the last 2 pollen seasons
* Sensitisation to birch pollen as demonstrated, at screening, by a positive SPT to birch pollen with wheal diameter greater than 3 mm and specific IgE levels \> 0.70 kU/L (birch pollen and rBet v 1)
* Patients asymptomatic to all other allergens during the birch pollen season
* RRTSS during the previous pollen season ≥ 12 out of a maximum possible score of 18
* Patients with an FEV1 ≥ 80% of the predicted value
* Female patients with no childbearing potential
* Female patients of childbearing potential are eligible if they are not sexually active or if they use a medically accepted contraceptive method and have a negative urine pregnancy test, and are willing and able to sign written informed consent stating that they will use appropriate contraception and not plan a pregnancy during this study
* Patients able to be compliant with respect to the completion of the daily record card and taking of the investigational products
* Patients having provided signed informed consent

Exclusion Criteria

* Patients with symptoms of rhinoconjunctivitis during the birch pollen season due to non-birch-related allergens
* Patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to house dust mites
* Patients with symptomatic allergic rhinitis/rhinoconjunctivitis due to cat or dog allergens, and living with these animals at home or at risk of frequent contacts with these animals (family, friends etc.) during the course of the study
* Patients who previously received desensitisation treatment to birch pollen and/or another Betulaceae sp. within the previous 10 years
* Patients with asthma (except birch seasonal asthma in which case the patient could be included in the study)
* Patients with any nasal or oral condition that could interfere with efficacy or safety assessments (such as nasal polyposis or oral inflammation)
* Patients with a past or current disease, which as judged by the investigator, may affect the patient's participation in or outcome of this study
* Any disease or condition which would place a patient at undue risk by being included in the study (according to the investigator's opinion)
* Usual contra-indications of immunotherapy such as concomitant local or systemic beta-blocker therapy and/or immunosuppressive drugs
* Patients with ongoing treatment by immunotherapy with another allergen
* Patients treated with inhaled/systemic steroids within 4 weeks prior to Screening, or with long acting systemic corticosteroids 12 weeks before Screening
* Patients under continuous corticotherapy or undergoing chronic treatment with H2-antihistamine drugs
* Known hypersensitivity to mannitol
* Pregnancy, breast-feeding/lactation or sexually active women of childbearing potential who are not using a medically accepted contraceptive method
* Patients with a history of drug or alcohol abuse

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No